$CANF News

Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026

Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes

Can-Fite BioPharma Files Prospectus For Offering ~6.599M Ordinary Shares On Behalf Of Selling Shareholders

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price

Can-Fite Says Blinded Overall Survival Observed Across Entire Patient Population In Ongoing Pivotal Phase III Study Of Namodenoson In Advanced HCC Appears Longer Than Originally Anticipated Based On Assumptions Underlying Study Design

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe Syndrome

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Can-Fite Pancreatic Cancer Data Accepted For ESMO Presentation, To Present Namodenoson Cancer Study Results At The Event

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027